Online inquiry

IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6443MR)

This product GTTS-WQ6443MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6443MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6097MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ1808MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ6152MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CP-675
GTTS-WQ4785MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ12001MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ7383MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ14524MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ4451MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW